JAK Inhibitors May Aid Hair Regrowth in Patients With Alopecia
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 19, 2023 -- Janus kinase (JAK) inhibitors are associated with more hair regrowth than placebo for patients with alopecia areata, according to a review published online June 27 in JAMA Network Open.
Ming Liu, Ph.D., from Lanzhou University in China, and colleagues conducted a systematic literature review to evaluate the effectiveness and safety associated with JAK inhibitors for alopecia areata. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.
Based on seven randomized controlled trials (1,710 patients), the researchers found that JAK inhibitors were associated with more patients achieving 50 percent improvement (odds ratio, 5.28; 95 percent confidence interval [CI], 1.69 to 16.46; GRADE assessment: low certainty) and 90 percent improvement (odds ratio, 8.15; 95 percent CI, 4.42 to 15.03; GRADE assessment: low certainty), based on the Severity of Alopecia Tool (SALT) score from baseline versus placebo. JAK inhibitors were associated with more reduced SALT scores from baseline versus placebo (mean difference, –34.52; GRADE assessment: moderate certainty); however, they were not associated with more treatment-related adverse events (relative risk, 1.25; 95 percent CI, 1.00 to 1.57; GRADE assessment: high certainty), including severe adverse events (relative risk, 0.77; 95 percent CI, 0.41 to 1.43; GRADE assessment: high certainty), versus placebo.
"These findings suggest that, although the safety and tolerability of JAK inhibitors were acceptable, longer trials are needed to further assess their effectiveness and safety for treatment of alopecia areata," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AAD: Continuous Improvements Seen Through 68 Weeks for Deuruxolitinib in Alopecia
TUESDAY, March 19, 2024 -- For adults with alopecia areata, continuous improvements are seen through 68 weeks with deuruxolitinib, according to a study presented at the annual...
AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia
MONDAY, March 18, 2024 -- Continuous treatment with baricitinib in patients with severe alopecia areata demonstrates improvement in hair regrowth outcomes through 76 weeks of...
New Side Effects Reported for GLP-1 RA Weight-Loss Drugs
THURSDAY, Jan. 4, 2024 -- In a quarterly report issued this week, the U.S. Food and Drug Administration said it is investigating cases of hair loss, aspiration, and suicidal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.